Equities
  • Price (USD)65.98
  • Today's Change0.153 / 0.23%
  • Shares traded1.13k
  • 1 Year change+14.38%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 17:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HLMA:LSE since
announced
Transaction
value
Rovers Medical Devices BVDeal completed03 Mar 202403 Mar 2024Deal completed11.34%92.12m
TeDan Surgical Innovations IncDeal completed20 Nov 202320 Nov 2023Deal completed24.84%100.00m
Tedan Surgical Innovations GmbHDeal completed20 Nov 202320 Nov 2023Deal completed24.84%--
Lazer Safe Pty LtdDeal completed04 Aug 202304 Aug 2023Deal completed20.16%29.48m
Data delayed at least 20 minutes, as of Jul 26 2024 16:49 BST.

Institutional shareholders

0.09%Per cent of shares held by top holders
HolderShares% Held
NFJ Investment Group LLCas of 28 Jun 2024167.40k0.09%
Tidal Investments LLCas of 03 Jul 20241.15k0.00%
PNC Investments LLCas of 31 Mar 2024139.000.00%
GAMMA Investing LLCas of 30 Jun 202439.000.00%
Amundi Asset Management US, Inc.as of 31 Mar 202417.000.00%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.